Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.52 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | GRK2 | P25098 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7952406 | 0.93 | HTT (0.43) | ALDH1A1LMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL24050283 | 0.90 | ALDH1A1 (0.52) | ALDH1A1LMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7951970 | 0.89 | HTT (0.41) | ALDH1A1LMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7957457 | 0.88 | TAAR1 (0.50) | ALDH1A1LMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL24050701 | 0.88 | ALDH1A1 (0.56) | ALDH1A1LMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL24050282 | 0.88 | ALDH1A1 (0.50) | ALDH1A1LMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7953000 | 0.87 | ALDH1A1 (0.47) | ALDH1A1LMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7952189 | 0.85 | TAAR1 (0.42) | ALDH1A1LMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL24050277 | 0.85 | SMN1; SMN2 (0.50) | ALDH1A1LMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7953157 | 0.84 | NAMPT (0.40) | ALDH1A1LMNACYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12209140-B2 | Therapeutics for the treatment of glaucoma | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2025-01-28 | — | — | US | disclosed |
| US-20230219912-A1 | HALOGENATED BENZOTHIADIAZINES FOR THE TREATMENT OF CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-07-13 | — | — | US | disclosed |
| US-20230219912-A1 | HALOGENATED BENZOTHIADIAZINES FOR THE TREATMENT OF CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-07-13 | — | — | US | disclosed |
| US-20230101009-A1 | THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2023-03-30 | — | — | US | disclosed |
| US-11505572-B2 | Therapeutics for the treatment of glaucoma | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2022-11-22 | — | — | US | disclosed |
| WO-2021236818-A1 | HALOGENATED BENZOTHIADIAZINES FOR THE TREATMENT OF CANCER | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2021-11-25 | — | — | WO | disclosed |
| US-10981951-B2 | Therapeutics for the treatment of glaucoma | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2021-04-20 | — | — | US | disclosed |
| US-20210040148-A1 | THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2021-02-11 | — | — | US | disclosed |
| US-20170002040-A1 | NOVEL THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2017-01-05 | — | — | US | disclosed |
| US-6242443-B1 | 1,2,4-benzothiadiazine derivatives, their preparation and use | NOVO NORDISK AIS (DK) | 2001-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219912-A1 | HALOGENATED BENZOTHIADIAZINES FOR THE TREATMENT OF CANCER | TFAM, NDUFAF1, NDUFV1 | ALDH1A1 1132/4885LMNA 4484/4885CYP1A2 536/4885 |
| US-20230101009-A1 | THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | KCNJ1, KCNJ2, KCNJ11 | ALDH1A1 943/4885LMNA 2093/4885CYP1A2 2573/4885 |
| US-20210040148-A1 | THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | KCNJ1, KCNJ2, KCNJ11 | ALDH1A1 943/4885LMNA 2093/4885CYP1A2 2573/4885 |
| US-12209140-B2 | Therapeutics for the treatment of glaucoma | KCNJ1, KCNJ2, KCNJ11 | ALDH1A1 943/4885LMNA 2093/4885CYP1A2 2573/4885 |
| US-20170002040-A1 | NOVEL THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | KCNJ1, KCNK4, KCNK2 | ALDH1A1 1014/4885LMNA 2066/4885CYP1A2 3097/4885 |
| US-11505572-B2 | Therapeutics for the treatment of glaucoma | KCNJ1, KCNJ2, KCNJ11 | ALDH1A1 943/4885LMNA 2093/4885CYP1A2 2573/4885 |
| US-10981951-B2 | Therapeutics for the treatment of glaucoma | KCNJ1, KCNJ2, KCNJ11 | ALDH1A1 943/4885LMNA 2093/4885CYP1A2 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.